ABSTRACT
BACKGROUND: Benznidazole and nifurtimox are effective drugs used to treat Chagas' disease; however, their administration in patients in the chronic phase of the disease is still limited, mainly due to their limited efficacy in the later chronic stage of the disease and to the adverse effects related to these drugs. OBJECTIVES: To evaluate the effect of low doses of nanoformulated benznidazole using a chronic model of Trypanosoma cruzi Nicaragua infection in C57BL/6J mice. METHODS: Nanoformulations were administered in two different schemes: one daily dose for 30 days or one dose every 7 days, 13 times. RESULTS: Both treatment schemes showed promising outcomes, such as the elimination of parasitaemia, a reduction in the levels of T. cruzi-specific antibodies and a reduction in T. cruzi-specific IFN-γ-producing cells, as well as an improvement in electrocardiographic alterations and a reduction in inflammation and fibrosis in the heart compared with untreated T. cruzi-infected animals. These results were also compared with those from our previous work on benznidazole administration, which was shown to be effective in the same chronic model. CONCLUSIONS: In this experimental model, intermittently administered benznidazole nanoformulations were as effective as those administered continuously; however, the total dose administered in the intermittent scheme was lower, indicating a promising therapeutic approach to Chagas' disease.
Subject(s)
Chagas Disease , Nitroimidazoles , Trypanocidal Agents , Trypanosoma cruzi , Animals , Chagas Disease/drug therapy , Humans , Mice , Mice, Inbred C57BL , Nicaragua , Nitroimidazoles/therapeutic use , Trypanocidal Agents/therapeutic useABSTRACT
The purpose of this study was to evaluate whether combined treatment with a cardiovascular exercise rehabilitation program and low doses of heparin can induce changes in ergometric parameters of ischemia in patients with coronary artery disease (CAD). Heparin may potentiate the development of new vessels promoted by ischemia and therefore may produce important clinical improvement. Thirty-six patients with stable CAD and evidence of myocardial ischemia on exercise testing were randomized into three groups: a control group (n = 11) received the usual medical treatment; another group (n = 11) underwent three exercise sessions per week during 12 weeks; and a third group (n = 14) undertook this exercise program and also received calcium heparin 12,500 IU subcutaneously 20 to 30 minutes before each exercise session. Pretreatment and posttreatment exercise tests were compared. Patients who underwent the rehabilitation program had an increase in exercise duration and workload at the onset of 1 mm ST-segment depression, but only patients who received calcium heparin showed a significant increase in rate-pressure product at the ST-segment ischemic threshold (p = 0.035). This result suggests that higher levels of myocardial oxygen consumption were now tolerated, a change that may be related to an improvement in myocardial perfusion.
Subject(s)
Coronary Disease/therapy , Exercise Therapy , Fibrinolytic Agents/therapeutic use , Heparin/therapeutic use , Coronary Disease/drug therapy , Coronary Disease/physiopathology , Coronary Disease/rehabilitation , Female , Humans , Male , Middle Aged , Oxygen Consumption , Treatment OutcomeABSTRACT
Sao descritos dois novos casos de sindrome dolorosa renal e pionefrose que envolve o grupo caliceal superior do rim, secundario a uma compressao extrinseca deste grupo caliceal. Patologia deste descrita por Elwin E. Fraley em 1966, pela primeira vez, a evolucao tem inicio com um simples retardo de esvaziamento do grupo caliceal superior do rim; tem um quadro clinico de simples dor lombar, ocorrendo no entanto o acometimento geral do orgao; o tratamento quase sempre cirurgico, dependendo da lesao, nao so em gravidade ou extensao, o procedimento consistira em infundibuloplastia simplesmente ou heminefrectomia